Ilaprazole has been investigated in Helicobacter Infections.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Amphetamine | Ilaprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dextroamphetamine | Ilaprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Fluconazole | The metabolism of Ilaprazole can be decreased when combined with Fluconazole. |
| Indinavir | Ilaprazole can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nelfinavir | The serum concentration of Nelfinavir can be decreased when it is combined with Ilaprazole. |
| Nilotinib | The serum concentration of Nilotinib can be decreased when it is combined with Ilaprazole. |
| Posaconazole | Ilaprazole can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Ilaprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rilpivirine | Ilaprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Ilaprazole can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | The serum concentration of Saquinavir can be increased when it is combined with Ilaprazole. |
| Voriconazole | The metabolism of Ilaprazole can be decreased when combined with Voriconazole. |
| Alendronic acid | The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Ilaprazole. |
| Ibandronate | The therapeutic efficacy of Ibandronate can be decreased when used in combination with Ilaprazole. |
| Clodronic acid | The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Ilaprazole. |
| Etidronic acid | The therapeutic efficacy of Etidronic acid can be decreased when used in combination with Ilaprazole. |
| Tiludronic acid | The therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Ilaprazole. |
| Incadronic acid | The therapeutic efficacy of Incadronic acid can be decreased when used in combination with Ilaprazole. |
| Tacrolimus | The metabolism of Tacrolimus can be decreased when combined with Ilaprazole. |
| Dacomitinib | Ilaprazole can cause a decrease in the absorption of Dacomitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | The excretion of Methotrexate can be decreased when combined with Ilaprazole. |
| Pexidartinib | The serum concentration of Pexidartinib can be decreased when it is combined with Ilaprazole. |
| Budesonide | Ilaprazole can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous sulfate anhydrous | Ilaprazole can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Selpercatinib | The serum concentration of Selpercatinib can be decreased when it is combined with Ilaprazole. |
| Doxycycline | Ilaprazole can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotorasib | The therapeutic efficacy of Sotorasib can be decreased when used in combination with Ilaprazole. |
| Belumosudil | The serum concentration of Belumosudil can be decreased when it is combined with Ilaprazole. |
| Levothyroxine | The absorption of Levothyroxine can be decreased when combined with Ilaprazole. |
| Sparsentan | The therapeutic efficacy of Sparsentan can be decreased when used in combination with Ilaprazole. |
| Bosutinib | The serum concentration of Ilaprazole can be decreased when it is combined with Bosutinib. |